Fluzone High Dose - Sanofi
Sanofi Pasteur Product Monograph 372 - FLUZONE® High-Dose Page 3 of 23 FLUZONE® High-Dose Influenza Virus Vaccine Trivalent Types A and B (Split Virion) PART I: HEALTH PROFESSIONAL INFORMATION SUMMARY PRODUCT INFORMATION Route of Administration: Intramuscular injection. Dosage Form/Strength: Suspension for injection. Active …
Information, Product, Monographs, Product information, Product monograph, Fluzone
Download Fluzone High Dose - Sanofi
Information
Domain:
Source:
Link to this page:
Please notify us if you found a problem with this document:
Documents from same domain
Lantus SOLOSTAR - Sanofi
products.sanofi.caPage 1 LANTUS ® SOLOSTAR ® Instruction Leaflet . SoloSTAR ® is a prefilled pen for the injection of insulin. Your health professional has decided that SoloSTAR is appropriate for you, based on your ability to handle SoloSTAR.
PRODUCT MONOGRAPH - Sanofi
products.sanofi.caPLAVIX Product Monograph Page 1 of 55 . PRODUCT MONOGRAPH . PrPLAVIX®. Clopidogrel Tablets, Manufacturer’s Standard . 75 …
Kayexalate (sodium polystyrene sulfonate) - Sanofi
products.sanofi.caKAYEXALATE (sodium polystyrene sulfonate) is a cream or light brown fine powder of sodium polystyrene sulfonate. KAYEXALATE is a cation-exchange resin prepared in the
Thymoglobulin (anti-thymocyte globulin [rabbit]) - …
products.sanofi.caLive vaccines should not be administered to patients about to receive, receiving, or after treatment with Thymoglobulin. Concomitant administration of Thymoglobulin with live virus
PRODUCT MONOGRAPH - Sanofi
products.sanofi.caCLOLAR® (clofarabine for injection) Page 1 of 41. PRODUCT MONOGRAPH . PrCLOLAR®. Clofarabine for injection . 1 mg/mL (20 mg/20 mL) Antineoplastic Agent . sanofi-aventis Canada Inc. 2905 Place Louis-R.-Renaud
Product, Monographs, Sanofi, Product monograph, Product monograph sanofi
Myochrysine (sodium aurothiolamate) - Sanofi
products.sanofi.ca3 It is usually used for treating patients who show evidence of continued or additional disease activity despite conservative drug therapy, e.g. with salicylates or …
PRODUCT MONOGRAPH INCLUDING PATIENT …
products.sanofi.caADLYXINE - Product Monograph Page 1 of 79. PRODUCT MONOGRAPH . INCLUDING PATIENT MEDICATION INFORMATION . Pr ADLYXINE™ . lixisenatide injection . 0.05 mg per mL (10 μg/dose)
Information, Product, Patients, Monographs, Medication, Including, Product monograph, Product monograph including patient, Including patient medication information
PRODUCT MONOGRAPH INCLUDING PATIENT …
products.sanofi.caPage 1 of 64. PRODUCT MONOGRAPH. INCLUDING PATIENT MEDICATION INFORMATION . PrPRALUENT®. alirocumab . solution for subcutaneous injection . 75 mg/mL and 150 mg/mL
Information, Product, Patients, Monographs, Medication, Including, Product monograph, Product monograph including patient, Including patient medication information
Renvela (sevelamer carbonate) - Sanofi
products.sanofi.caRenvela (sevelamer carbonate) Product Monograph Page 1 of 21. PRODUCT MONOGRAPH . PrRENVELA®. sevelamer carbonate tablets . 800 mg . Phosphate Binder . ATC code: VO3A EO2
PRODUCT MONOGRAPH LANTUS - Sanofi
products.sanofi.caPage 1 of 62 . PRODUCT MONOGRAPH . LANTUS®. Insulin glargine injection (rDNA origin) Solution for injection 100 U/mL . ATC code: A10AE04 . Antidiabetic Agent
Product, Monographs, Product monograph, Lantus, Product monograph lantus
Related documents
MATERIAL SAFETY DATA SHEET 1. Product and Company ...
www.rbnainfo.comMar 26, 2010 · Isopropanol 67-63-0 Monograph 71 [1999]; Supplement 7 [1987]; Monograph 15 [1977] Carcinogenicity The finished product is not expected to have chronic health effects. space Mutagenicity The finished product is not expected to have chronic health effects. space Reproductive effects The finished product is not expected to have chronic health ...
PRODUCT MONOGRAPH
pdf.hres.caPRODUCT MONOGRAPH DUKORAL® Oral, Inactivated Cholera and ETEC Diarrhea Vaccine Oral Suspension Active Immunizing Agent for the Prevention of Diarrhea Caused by Vibrio cholerae and/or heat-labile toxin producing Enterotoxigenic Escherichia coli ATC Code: J07AE01 Manufactured by: Date of Approval: Valneva Sweden AB,
PRODUCT MONOGRAPH
pdf.hres.caPRODUCT MONOGRAPH Pr WELLBUTRIN ... PART III: CONSUMER INFORMATION ... symptoms including delusions, hallucinations, psychosis, concentration disturbance, paranoia and confusion. In some cases these abated upon dose reduction and/or withdrawal of treatment.
Information, Product, Monographs, Consumer, Including, Product monograph, Consumer information
Forxiga Consumer Information - AstraZeneca
www.astrazeneca.caProduct Monograph Master Template Template date: September 2020 FORXIGA (dapagliflozin propanediol monohydrate) Page 3 of 8 COPYRIGHT 2014-2021 ASTRAZENECA CANADA INC FORXIGA and when to start taking it again. have a sudden reduction in your insulin dose have a history of DKA. • are older than 65 years of age
Information, Product, Monographs, Consumer, Product monograph, Consumer information
PRODUCT MONOGRAPH SYMBICORT …
www.astrazeneca.caindicated for the maintenance treatment of moderate to severe COPD including chronic bronchitis and emphysema, in patients with persistent symptoms and a history of exacerbations, where the use of a combination product is considered appropriate. SYMBICORTTURBUHALER is NOT indicated for the relief of acute bronchospasm in COPD patients.
PART III: CONSUMER INFORMATION INSPIOLTO RESPIMAT …
www.boehringer-ingelheim.caInspiolto® Respimat ® Product Monograph Page 43 of 50 PART III: CONSUMER INFORMATION ... CONSUMER INFORMATION . ... including drugs prescribed by other doctors, vitamins, minerals, natural supplements, or alternative medicines. ...
Information, Product, Monographs, Consumer, Including, Product monograph, Consumer information
PRODUCT MONOGRAPH - Pfizer Canada
www.pfizer.caPrevnar® 13 (Pneumococcal 13-valent Conjugate Vaccine) Product Monograph Page 7of 61 3. Adults 18Years and Older Safety was assessed in 7 clinical studies including 91,593 adults ranging in ages from 18 to 101 years. Prevnar 13 was administered to 48,806 adults; 2,616 adults were aged 50-64 years and 45,291 adults were 65 years and older.
Labeling <7> Type of Posting Posting Date Official Date ...
www.uspnf.comAug 30, 2019 · , Monograph Naming Policy for Salt Drug Substances in Drug Products and Compounded Preparations). Labeling The labeling clearly states the specific salt form of the active moiety that is present in the product or preparation because this information may be useful to practitioners and patients. The names and strengths of both the active moiety ...